Patents by Inventor Edward E. Max

Edward E. Max has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant human IgA-J chain dimer
    Patent number: 6673342
    Abstract: Disclosed are compositions and methods of use that comprise engineered IgA antibodies that, when administered to a host are secreted across the epithelium into the mucosal barriers of the body providing external passive immunotherapy against agents such as viral, bacterial and eukaryotic pathogens. Also disclosed are mini antibodies comprising the minimal transcytosis domains.
    Type: Grant
    Filed: May 16, 2000
    Date of Patent: January 6, 2004
    Assignees: Bond of Regents, The University of Texas System, The United States of America as represented by the Department of Health and Human Services
    Inventors: J. Donald Capra, Jonathan M. Hexham, Leon N. Carayannopoulos, Edward E. Max
  • Recombinant human IGA-J. chain dimer
    Patent number: 6063905
    Abstract: Disclosed are compositions and methods of use that comprise engineered IgA antibodies that, when administered to a host are secreted across the epithelium into the mucosal barriers of the body providing external passive immunotherapy against agents such as viral, bacterial and eukaryotic pathogens. Also disclosed are mini antibodies comprising the minimal transcytosis domains.
    Type: Grant
    Filed: January 7, 1997
    Date of Patent: May 16, 2000
    Assignees: Board of Regents, The University of Texas System, The United States of America as represented by the Department of Health and Human Services
    Inventors: J. Donald Capra, Jonathan M. Hexham, Leon N. Carayannopoulos, Edward E. Max
  • IgE isoforms and methods of use
    Patent number: 6043345
    Abstract: Methods and compositions are provided relating to novel IgE isoforms and their use in immune hypersensitivity diagnosis and treatment. The compositions include transcription and translation products of the immunoglobulin epsilon locus, specific probes for epsilon transcription products, and compounds that specifically bind epitopes of epsilon translation products. Novel products of the epsilon locus include the following transcription products and translation products thereof: CH4-M2", CH4'-CH5-M1'-M2, CH4'-CH5-M2', CH4'-CH5-M2.increment. and CH4-M2'. Such epsilon products, specific probes and binding compounds find use in methods and kits for immune hypersensitivity diagnosis and treatment.
    Type: Grant
    Filed: February 14, 1996
    Date of Patent: March 28, 2000
    Assignee: The Regents of the University of California
    Inventors: Andrew Saxon, Ke Zhang, Edward E. Max, Jeffrey B. Lyczak, Sherie L. Morrison
  • IgE isoforms and methods of use
    Patent number: 5552537
    Abstract: Methods and compositions are provided relating to novel IgE isoforms and their use in immune hypersensitivity diagnosis and treatment. The compositions include transcription and translation products of the immunoglobulin epsilon locus, specific probes for epsilon transcription products, and compounds which specifically bind epitopes of epsilon translation products. Novel products of the epsilon locus include the following transcription products and translation products thereof: CH4-M2", SEQ ID NO:02, residues 1-107 and, (SEQ. ID NO:06, CH4'-CH5-M1'-M2, (see SEQ ID NO:02, residues 1-72,SEQ ID NO:03 and SEQ ID NO:05) CH4'-CH5-M2'(SEQ ID NO:02, residues 1-72, SEQ ID NO:03 and SEQ ID NO:07 and CH4'-CH5-M2" (SEQ ID NO:02, residues 1-72, SEQ ID NO:03 and SEQ ID NO:06). Such epsilon products, specific probes and binding compounds find use in methods and kits for immune hypersensitivity diagnosis and treatment.
    Type: Grant
    Filed: March 24, 1993
    Date of Patent: September 3, 1996
    Assignee: The Regents of the University of California
    Inventors: Andrew Saxon, Ke Zhang, Edward E. Max